Eolo Pharma has developed a compound, which we called MVD1, that has anti-obesity properties when tested in preclinical models. By preventing and treating obesity, MVD1 also improves glucose metabolism, making it attractive for the treatment of type II diabetes also. Furthermore, MVD1 shows better results than Metformin, the first line drug for the treatments of type II diabetes in patients. MVD1 works through a completely novel pharmacological action, stimulating resting energy expenditure and fat burning without the need of extra exercise. Together, these data demonstrate MVD1 as a candidate for the treatment of obesity, type II diabetes. Based on that, we aimed to follow the pre-clinical development necessary to perform a Phase IB clinical trial in patients. MVD1 complied with all the required safety requirements by regulatory agencies, strongly suggesting that it may be suitable for further clinical development.